 |
|
|
|
 |
| Bladder cancer is the fifth most common cancer in the United States - the fourth most frequently diagnosed cancer in men and the ninth in women. In fact,
the American Cancer Society estimates that there will be more than 63,000 new cases of bladder cancer diagnosed in the United States in 2005. Accurate and early
diagnosis of bladder cancer is critical to successful treatment. Inverness Medical Professional Diagnostics offers the first and only NMP22 ELISA test for the screening and monitoring of this important
disease, the NMP22® Test Kit*, which detects elevated levels of NMP22 protein in
the urine of patients with bladder cancer, even in the early stages of disease. |
|
| *Manufactured by Matritech, Inc., for Inverness Medical Professional Diagnostics. |
|
| |
|
| Useful Downloads |
|
|
|
 |
| |
|
